EVO756 — Topline data
Sep 2026
The Company expects to report top-line data in September 2026 for the fully-enrolled Phase 2b dose-ranging clinical trial (N=120) in moderate-to-severe AD patients.Source filing
EVMN biotech catalysts & pipeline
EVOMMUNE INC · Data as of 2026-09-08
Upcoming catalysts
EVO756 — Topline data
2027
Top-line data from the trial are expected in 2027.Source filing